Semaglutide in the UK: Wegovy, Ozempic & NHS Access Guide (2026)

Overview

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and is among the most widely used medications for weight management and type 2 diabetes globally. In the UK, semaglutide is available under two brand names: Ozempic (at doses of 0.5 mg, 1 mg, and 2 mg for type 2 diabetes) and Wegovy (at 2.4 mg for chronic weight management). Both are approved by the MHRA and available through NHS and private routes. The UK has seen explosive growth in demand for semaglutide since 2022, driven by high-profile media coverage and growing clinical evidence for its weight loss efficacy. The STEP 1 trial demonstrated an average weight loss of 14.9% with semaglutide 2.4 mg at 68 weeks — a result that helped Wegovy secure NICE approval and NHS commissioning. This guide explains the difference between Wegovy and Ozempic in the UK, how to access them on the NHS, private prescription options including Boots and Superdrug Online Doctor, and what patients can realistically expect from treatment.

Wegovy vs Ozempic: What's the Difference in the UK?

Semaglutide is the active ingredient in both Ozempic and Wegovy — the molecule is identical, but the formulations, doses, and licensed indications differ. Ozempic is available in 0.5 mg, 1 mg, and 2 mg doses, licensed for type 2 diabetes. Wegovy is available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses, with the 2.4 mg maintenance dose licensed for chronic weight management in obesity. The delivery devices also differ: Ozempic uses a reusable multi-dose injection pen, while Wegovy uses single-use pre-filled pens for each dose step. Both are injected subcutaneously once a week. On the NHS, the two drugs follow completely different prescribing pathways, and NHS prescribers cannot substitute one for the other. However, in the private market, some services prescribe Ozempic off-label for weight loss due to the supply issues that have historically affected Wegovy in the UK.

• Ozempic: semaglutide 0.5–2 mg — licensed for type 2 diabetes
• Wegovy: semaglutide 0.25–2.4 mg — licensed for chronic weight management
• Same molecule, different dose ranges and injection devices
• NHS: completely separate prescribing pathways — cannot be swapped
• Private: Ozempic sometimes prescribed off-label for weight loss when Wegovy is unavailable

NHS Wegovy: Eligibility Under NICE TA964

NICE Technology Appraisal TA964, approved in March 2023, recommends Wegovy (semaglutide 2.4 mg) for chronic weight management in adults meeting all of the following criteria: BMI of 35 kg/m² or above (or 30 kg/m² or above for patients from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds), at least one weight-related comorbidity (e.g., type 2 diabetes, hypertension, cardiovascular disease, obstructive sleep apnoea), and enrolment in a specialist NHS Tier 3 weight management service. NHS England has set a phased access plan for Wegovy, with priority initially given to those with the highest clinical need. As of 2026, rollout is ongoing with access expanding across integrated care boards (ICBs). Treatment is limited to 2 years and requires achievement of specified weight loss milestones to continue.

• NICE TA964 approved Wegovy for NHS use in England in March 2023
• BMI ≥35 (or ≥30 for certain ethnic groups) required
• At least one weight-related comorbidity required
• Must be enrolled in Tier 3 specialist weight management service
• NHS access phased — priority to highest clinical need
• Maximum 2 years treatment; milestone checks at 3 and 6 months

NHS Ozempic for Type 2 Diabetes

Ozempic is available on the NHS for adults with type 2 diabetes who meet criteria under NICE guidance TA572 and subsequent updates. It is typically offered when blood glucose is inadequately controlled on other medications such as metformin, and when GLP-1 receptor agonist therapy is appropriate — particularly in patients with established cardiovascular disease or high cardiovascular risk, where semaglutide has demonstrated cardiovascular outcome benefits. NHS GPs and diabetes care teams can prescribe Ozempic directly without requiring a Tier 3 referral, making the T2D pathway faster than the obesity pathway. Patients with T2D who use Ozempic will often lose 5–7% of their body weight as a secondary benefit, though weight loss alone is not an NHS indication for Ozempic prescribing.

Private Semaglutide in the UK: Boots, Superdrug & Others

For those unable or unwilling to wait for NHS access, private semaglutide prescriptions are widely available across the UK. Major high-street providers have built significant online prescribing services: **Boots Online Doctor** offers a weight management service using Wegovy, with consultations conducted via an online questionnaire and clinician review. Prescriptions are fulfilled and delivered by Boots Pharmacy. Typical cost is around £169–229 per month depending on dose. **Superdrug Online Doctor** similarly offers semaglutide (Wegovy) via an online consultation model. Costs are broadly comparable to Boots. **Juniper** is a specialist online weight management platform offering semaglutide and tirzepatide programmes with ongoing nurse and dietitian support, typically priced at £149–199/month. Other providers include Manual, Voy (Vitality), and Numan.

• Boots Online Doctor: Wegovy prescriptions ~£169–229/month
• Superdrug Online Doctor: Wegovy prescriptions ~£165–220/month
• Juniper: semaglutide programme ~£149–199/month with nurse/dietitian support
• Manual / Voy / Numan: competing private platforms, similar price range
• All require online or in-person medical consultation before prescribing
• Prescription-only medication — must go through a registered prescriber

Semaglutide Supply in the UK: 2026 Update

Semaglutide supply in the UK has been subject to significant fluctuations since 2022. Both Ozempic and Wegovy have faced availability constraints at various points, driven by global demand outpacing Novo Nordisk's manufacturing capacity. As of 2026, the supply situation has stabilised considerably, with Wegovy in particular seeing improved availability in UK pharmacies. The MHRA and NHS England previously issued joint guidance urging prescribers to prioritise Ozempic for T2D patients and avoid off-label weight loss prescribing that could divert supply. With Wegovy production scaled up, the pressure on Ozempic supply has eased. Private platforms now generally have consistent access to both formulations, though patients should confirm availability with their specific provider before starting treatment.

Semaglutide Side Effects: UK Patient Information

The most common side effects of semaglutide in UK patients are gastrointestinal and include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These are most pronounced during the dose escalation period and typically improve as the body adjusts to each dose level. The standard UK Wegovy titration starts at 0.25 mg/week for 4 weeks before incrementally increasing every 4 weeks toward the 2.4 mg maintenance dose. The MHRA has issued guidance consistent with global regulatory positions on the rare risks of pancreatitis, gallbladder disease, and — based on animal studies — a theoretical thyroid C-cell tumour risk. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). UK prescribers screen for these contraindications during the initial consultation.

• Very common: nausea, vomiting, diarrhoea, constipation — worst during titration
• Titration: start at 0.25 mg/week, increase every 4 weeks to 2.4 mg
• Rare: pancreatitis, gallbladder disease — seek immediate care if severe abdominal pain
• Contraindicated: personal or family history of medullary thyroid carcinoma or MEN2
• Not recommended in pregnancy — use effective contraception during treatment

References

1. NICE Technology Appraisal TA964: Semaglutide for Managing Overweight and Obesity (2023)
2. MHRA: Wegovy (Semaglutide 2.4 mg) UK Product Approval (2023)
3. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (2021) — PubMed
4. NHS England: Wegovy Rollout and Commissioning Guidance (2024)